簡介
(2R,3R,4R,5S,6S)-2-(乙酰氧基甲基)-6-(4-氯-3-(4-乙氧基芐基)苯基)四氫-2H-吡喃-3,4,5-三乙酸酯的CAS號是461432-25-7。分子式是C29H33ClO10,分子量為577.01932。
應用
(2R,3R,4R,5S,6S)-2-(乙酰氧基甲基)-6-(4-氯-3-(4-乙氧基芐基)苯基)四氫-2H-吡喃-3,4,5-三乙酸酯可用作化工中間體,用于有機合成及實驗研究。常用作有機化工原料,可用于制作香料,也是制藥工業(yè)成中合成多種藥物的中間體。也可以以合成席夫堿,測定食品等含有的痕量稀土金屬離子[1-2]。此外,(2R,3R,4R,5S,6S)-2-(乙酰氧基甲基)-6-(4-氯-3-(4-乙氧基芐基)苯基)四氫-2H-吡喃-3,4,5-三乙酸酯主要用途充當藥物合成的中間體[3]。根據(jù)現(xiàn)有文獻,(2R,3R,4R,5S,6S)-2-(乙酰氧基甲基)-6-(4-氯-3-(4-乙氧基芐基)苯基)四氫-2H-吡喃-3,4,5-三乙酸酯在驅蟲藥、抗艾滋病毒藥、抗乙肝病毒及抗感冒藥、抗風濕藥、抗組胺藥、抗糖尿病藥及抗癌癥藥等數(shù)萬種藥物合成中可能扮演著重要角色[4-6]。
危害
(2R,3R,4R,5S,6S)-2-(乙酰氧基甲基)-6-(4-氯-3-(4-乙氧基芐基)苯基)四氫-2H-吡喃-3,4,5-三乙酸酯對環(huán)境可能有危害,對水體應給予特別注意。此外,其對眼及上呼吸道有刺激作用。高濃度吸入后,輕者有欣快或窒息感,繼之出現(xiàn)抑郁、肌無力、嘔吐;重者意識喪失、大小便失禁、強直性痙攣、血壓下降。誤服可致死。長期接觸此物質會出現(xiàn)頭暈、頭痛、失眠、步態(tài)不穩(wěn)及消化道功能紊亂,嚴重可導致肝腎損害。
泄露處理
(2R,3R,4R,5S,6S)-2-(乙酰氧基甲基)-6-(4-氯-3-(4-乙氧基芐基)苯基)四氫-2H-吡喃-3,4,5-三乙酸酯一旦被大量泄露,應迅速撤離泄漏污染區(qū)人員至安全區(qū),并進行隔離,嚴格限制出入。切斷火源。建議應急處理人員戴自給正壓式呼吸器,穿防毒服。盡可能切斷泄漏源。防止流入下水道、排洪溝等限制性空間。當小量泄漏時,可以用砂土、干燥石灰或蘇打灰混合。也可以用大量水沖洗,洗水稀釋后放入廢水系統(tǒng)。
參考文獻
[1] S.D. Barrett, D.A. Bochar, L.L. Blazer, F.L. Ciske, G.W. Endres, J.K. Johnson, G.S. Keyes, R.S. Sidhu, R.C. Trievel, M.L. Collins, Fluorescent reporters for assays that measure competitive binding of test compounds with proteins binding S-adenosyl methionine, Cayman Chemical Company, Incorporated, USA; University of Michigan . 2012, p. 163pp.
[2] O. Da Silva, N. Probst, C. Landry, A.-S. Hanak, P. Warnault, C. Coisne, A.-G. Calas, F. Gosselet, C. Courageux, A.-J. Gastellier, M. Trancart, R. Baati, M.-P. Dehouck, L. Jean, F. Nachon, P.-Y. Renard, J. Dias, A New Class of Bi- and Trifunctional Sugar Oximes as Antidotes against Organophosphorus Poisoning, J. Med. Chem. 65(6) (2022) 4649-4666.
[3] C. He, L. Huang, J. Tonra, Preparation of tucaresol derivatives as anticancer agents, BeyondSpring Pharmaceuticals, Inc., USA . 2021, p. 67pp.
[4] Y. Jain, R. Gupta, P. Yadav, M. Kumari, Chemical Waltz of Organic Molecules "On Water": Saline-Assisted Sustainable Regioselective Synthesis of Fluorogenic Heterobioconjugates via Click Reaction, ACS Omega 4(2) (2019) 3582-3592.
[5] R.J. Shirey, D. Globisch, L.M. Eubanks, M.S. Hixon, K.D. Janda, Noninvasive Urine Biomarker Lateral Flow Immunoassay for Monitoring Active Onchocerciasis, ACS Infect. Dis. 4(10) (2018) 1423-1431.